Interní Med. 2018; 20(3): 144-146 | DOI: 10.36290/int.2018.026

New oral anticoagulants and gastroenterology

MUDr. PharmDr. Kamil Rudolf, Ph.D., MBA
II. interní gastroenterologická klinika Fakultní nemocnice v Hradci Králové

New oral anticoagulants, also known as direct oral anticoagulants due to their direct inhibitory effects towards thrombin or factorXa, represent a progressive group of antithrombotic drugs in clinical therapy. Regarding alimentary tract, it is necessary to respectthe pharmacokinetic processes of absorption and metabolic conversion of effective compounds to achieve the particular pharmacologicaleffect. In addition, particular risks of bleeding, dyspeptic discomfort and hepatopathy are to be concerned too. Theevaluation of the actual risk of bleeding versus thrombotic complication introduces the special case of intervention endoscopicgastroenterology.

Keywords: direct oral anticoagulants, pharmacokinetics, bleeding, endoscopy

Published: July 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rudolf K. New oral anticoagulants and gastroenterology. Interní Med. 2018;20(3):144-146. doi: 10.36290/int.2018.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic reviewand network meta-Analysis. PLoS One 2015; 30: e014856. Go to original source...
    2. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patiens with atrial fibrillation: a meta-analysis od randomised trials. Lancet 2014; 383: 955-962. Go to original source... Go to PubMed...
    3. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. Br Med J 2015; 350: h1857. Go to original source... Go to PubMed...
    4. Desai J, Kolb JM, Weitz JI, et al. Gastrointestinal bleeding with the new oral anticoagulants - defining the issues and the management strategies. Thromb Haemost 2013; 110: 205-212. Go to original source... Go to PubMed...
    5. Brighton T. New oral anticoagulant drugs - mechanisms of action. Aust Prescr 2010; 33: 38-41. Go to original source...
    6. Moore KT, Krook MA, Vaidyanathan S, Sarich TC, Damaruju CV, Fields LE. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in heatlhy adults when administered orally or via nasogastric tube. Clin Pharmacol Durg Dev. 2014; 3(4): 321-327. Go to original source... Go to PubMed...
    7. Stampfuss J, Kubitza D, Becka M, et al. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013; 51: 549-561. Go to original source... Go to PubMed...
    8. Frost Ch, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013; 75(2): 476-487. Go to original source... Go to PubMed...
    9. Song Y, Wang X, Perlstein I, et al. Relative bioavailability of apixaban solution or crusched tablet formulations administered by mouth or nasogastric tube in healthy subjects. Clin Ther. 2015; 37(8): 1703-1712. Go to original source... Go to PubMed...
    10. Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014; 14(2): 147-154. Go to original source... Go to PubMed...
    11. Parasrampuria DA, Truitt KE. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet. 2016; 55: 641-655. Go to original source... Go to PubMed...
    12. Abraham NS, Noseworthy PA, et al. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology 2017; 152: 1014. Go to original source... Go to PubMed...
    13. Veitch AM, Vanbiervliet G, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy. 2016 Apr; 48(4): 385-402. Go to original source... Go to PubMed...
    14. Deutsch D, Boustiére Ch, et al. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap Adv Gastroenterol. 2017 Jun; 10(6): 495-505. Go to original source... Go to PubMed...
    15. Chan EW, Lau WC, Leung WK, et al. Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Gastroenterology. 2015 Sep; 149(3): 586-95. Go to original source... Go to PubMed...
    16. Vítek P, Mikoviny Kajzlíková I. Antikoagulační a protidestičková léčba u endoskopických výkonů. Interní Med. 2013; 15(11-12): 355-357.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.